Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes
Triple negative breast cancers (TNBCs) are characterized by worse prognosis, higher propensity to earlier metastases, and shorter survival after recurrence compared with other breast cancer subtypes. Anthracycline- and taxane-based chemotherapy is still the mainstay of treatment in early stages, alt...
Main Authors: | Anna Diana, Francesca Carlino, Elisena Franzese, Olga Oikonomidou, Carmen Criscitiello, Ferdinando De Vita, Fortunato Ciardiello, Michele Orditura |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-03-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/4/819 |
Similar Items
-
Immune-Based Therapy in Triple-Negative Breast Cancer: From Molecular Biology to Clinical Practice
by: Francesca Carlino, et al.
Published: (2022-04-01) -
Immunohistochemical expression of PARP-1 in triple-negative endometrial cancer – a comparison of different score systems
by: Michał Bulsa, et al.
Published: (2023-03-01) -
Modern Immunotherapy in the Treatment of Triple-Negative Breast Cancer
by: Jakub Wesolowski, et al.
Published: (2022-08-01) -
Systemic Therapy De-Escalation in Early-Stage Triple-Negative Breast Cancer: Dawn of a New Era?
by: Ravi Kumar Gupta, et al.
Published: (2022-04-01) -
Long-term complete response with third-line PARP inhibitor after immunotherapy in a patient with triple-negative breast cancer: a case report
by: Roberta Caputo, et al.
Published: (2023-08-01)